Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate SOPHiA GENETICS SA before investing.

In this article, we go over a few key elements for understanding SOPHiA GENETICS SA’s stock price such as:

• SOPHiA GENETICS SA’s current stock price and volume
• Why SOPHiA GENETICS SA’s stock price changed recently
• Upgrades and downgrades for SOPH from analysts
• SOPH’s stock price momentum as measured by its relative strength

About SOPHiA GENETICS SA (SOPH)

Before we jump into SOPHiA GENETICS SA’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. The company has a partnership with Synnovis to bring blood-based cancer testing to patients in the United Kingdom. The company was incorporated in 2011 and is based in Rolle, Switzerland.

Want to learn more about SOPHiA GENETICS SA’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about SOPHiA GENETICS SA.

SOPHiA GENETICS SA’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, SOPHiA GENETICS SA’s stock price was $5.670.

SOPHiA GENETICS SA is down 1.56% from its previous closing price of $5.760.

During the last market session, SOPHiA GENETICS SA’s stock traded between $5.550 and $5.860. Currently, there are approximately 71.14 million shares outstanding for SOPHiA GENETICS SA.

SOPHiA GENETICS SA’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

SOPHiA GENETICS SA Stock Price History

SOPHiA GENETICS SA’s (SOPH) price is currently down 1.73% so far this month.

During the month of July, SOPHiA GENETICS SA’s stock price has reached a high of $6.770 and a low of $4.950.

Over the last year, SOPHiA GENETICS SA has hit prices as high as $6.770 and as low as $2.920. Year to date, SOPHiA GENETICS SA’s stock is up 21.41%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused SOPHiA GENETICS SA Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there was 1 analyst who downgraded SOPHiA GENETICS SA’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate SOPHiA GENETICS SA’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on SOPHiA GENETICS SA’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

SOPHiA GENETICS SA’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about SOPHiA GENETICS SA (SOPH) by visiting AAII Stock Evaluator.

Relative Price Strength of SOPHiA GENETICS SA

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, SOPHiA GENETICS SA has a weighted four-quarter relative price strength of 10.24%, which translates to a Momentum Score of 83 and is considered to be Very Strong.

Want to learn more about how SOPHiA GENETICS SA is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

SOPHiA GENETICS SA Stock Price: Bottom Line

As of July 31, 2026, SOPHiA GENETICS SA’s stock price is $5.670, which is down 1.56% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like SOPHiA GENETICS SA stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.